GenSight Biologics Secures Early Access Approvals for LHON Gene Therapy

Event summary

  • GenSight Biologics received approval for 15-20 patients in France's Named Patient Early Access (AAC) program, with treatments scheduled for mid-to-late March 2026.
  • A second patient in Israel was approved for treatment under the Paid Named Patient Program, with treatment expected by next quarter.
  • The FDA cleared a second Individual IND for the expanded access program in the US, following the first treatment in January 2026.
  • First payments for treatments in France are expected before the end of March 2026, with aggregate revenues ensuring operational continuity through 2026.

The big picture

GenSight Biologics is leveraging early access programs to generate critical revenue while advancing its gene therapy for Leber Hereditary Optic Neuropathy (LHON). The strategic move aligns with broader industry trends of biopharma companies using named patient programs to bridge funding gaps during clinical development. The approvals in France, Israel, and the US highlight the company's ability to navigate diverse regulatory landscapes, potentially setting a precedent for other rare disease therapies.

What we're watching

Revenue Impact
Whether the early access program revenues will be sufficient to extend the cash runway beyond 2026 and support the RECOVER Phase III trial.
Regulatory Momentum
The pace at which additional regulatory approvals for early access programs will be secured in other regions.
Clinical Progress
How the ongoing REVISE dose-ranging study will influence the strategic direction of GS010/LUMEVOQ's development.

Related topics

Regulatory Approval